WO1997024355A1 - Pyrido (2,3-b) pyrazine derivatives - Google Patents
Pyrido (2,3-b) pyrazine derivatives Download PDFInfo
- Publication number
- WO1997024355A1 WO1997024355A1 PCT/JP1996/003666 JP9603666W WO9724355A1 WO 1997024355 A1 WO1997024355 A1 WO 1997024355A1 JP 9603666 W JP9603666 W JP 9603666W WO 9724355 A1 WO9724355 A1 WO 9724355A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkenyl
- pyridyl
- phenyl
- amino
- alkenoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- This invention relates to new heterobicyclic derivatives.
- One object of this invention is to provide the new and useful pyridopyrazme derivatives and pharmaceutically acceptable salts thereof which possess a strong phosphodiesterase IV (PDE IV) -inhibitory activity and a strong inhibitory activity on the production of tumor necrosis factor (TNF) .
- Another object of this invention is to provide processes for preparation of the pyridopyrazme derivatives and salts thereof.
- the object pyridopyrazme derivatives of the present invention are novel and can be represented by the following general formula (I) :
- R 1 is pyridyl (lower)alkyl, N-oxidopyridyl (lower)alkyl or imidazolyl (lower)alkyl
- R 2 is aminophenyl, [protected amino]phenyl
- the object compound (I) of the present invention can be prepared by the following processes.
- R! and R 2 are each as defined above, R ⁇ is [aminopyridyl] (lower)alkenyl, R ⁇ is [acylaminopyridyl] (lower) alkenyl, R is [lower alkanoyla ino]phenyl,
- Rf is [lower alkanoylamino]phenyl, [[[halophenyl] (lower) alkenoyl]amino]phenyl, [ [pyridyl (lower) alkenoyl]amino]phenyl, [ [ [N-oxidopyridyl] (lower)alkenoyl]amino]phenyl, [[[protected aminopyridyl] (lower) alkenoyl]amino]- phenyl or [thiazolylcarbonylamino]phenyl which may have pyridyl,
- R 3 is lower alkanoyl, [halophenyl] (lower) alkenoyl, pyridyl (lower) alkenoyl, [N-oxidopyridyl] (lower) - alkenoyl, [protected aminopyridyl] (lower) alkenoyl or thiazoylcarbonyl which may have pyridyl, R 4 is N-protective group, Y is halogen,
- Y ⁇ is halide
- A is lower alkylene.
- the starting compound (II) of the present invention can be prepared by the following processes.
- R 2 , R 2 , R 2 and R 3 are each as defined above,
- R 5 is lower alkyl
- R 6 is protected aminophenyl
- R' is aminophenyl
- R 8 is dihalophenyl, N-oxidopyridyl, aminopyridyl, protected aminopyridyl, carboxypyridyl, protected carboxypyridyl, [pyridyl (lower) alkenyl]pyridyl, [carboxy(lower) alkenyl]pyridyl or [protected carboxy(lower) alkenyl]pyridyl, q
- R ⁇ is halo (lower) alkyl
- X 1 , X 2 , X 3 , X 4 and X are each a leaving group
- Q is lower alkenylene.
- Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamme salt, N,N'-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic or sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maleate, tart
- lower is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.
- higher is used to intend a group having 7 to 20 carbon atoms, unless otherwise provided.
- Suitable “lower alkyl” and “lower alkyl moiety” in the terms “pyridyl (lower)alkyl", “N-oxidopyridyl (lower)- alkyl”, “imidazolyl (lower)alkyl”, “lower alkylbenzothiazolyl” and “halo (lower) alkyl” may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, hexyl, and the like, and in which more preferable example may be C ⁇ -C alkyl, and the most preferable one may be methyl.
- lower alkenyl and “lower alkenyl moiety” in the terms " [dihalophenyl] (lower) alkenyl", “[N-oxido ⁇ yridyl] (lower) alkenyl”, “[aminopyridyl] (lower) alkenyl”, “[protected aminopyridyl] (lower) alkenyl”, “[carboxypyridyl] (lower) alkenyl”,
- [[protected carboxy(lower)alkenyl]pyridyl] (lower)alkenyl” and " [pyridyl (lower)alkenyl]pyridyl” may include vinyl, 1- (or 2-)propenyl, l-(or 2- or 3-)butenyl, 1- (or 2- or 3- or 4-)pentenyl, 1- (or 2- or 3- or 4- or 5-)hexenyl, methylvinyl, ethylvinyl, l-(or 2- or 3-)methyl-l- (or 2-)- propenyl, 1- (or 2- or 3-) thyl-1- (or 2-)propenyl, 1- (or 2- or 3- or 4-)methyl-l- (or 2- or 3-)butenyl, and the like, in which more preferable example may be C2-C4 alkenyl, and the most preferable one may be vinyl.
- Suitable “lower alkynyl” may include ethynyl, 1-propynyl, propargyl, 1-methylpropargyl, 1 or 2 or 3- butynyl, 1 or 2 or 3 or 4-pentynyl, 1 or 2 or 3 or 4 or 5- hexynyl, and the like.
- Suitable “lower alkoxy” may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, t-pentyloxy, hexyloxy and the like.
- Suitable “lower alkylene” may include straight or branched one such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, ethylethylene, propylene, and the like, in which more preferable example may be C ] _-C 4 alkylene and the most preferable one may be methylene.
- Suitable "lower alkenylene” may include straight or branched one having 2 to 6 carbon atom(s) such as vinylene, propenylene, 1- (or 2-)butenylene, l-(or 2- or 3-)pentenylene, 1- (or 2- or 3-)hexenylene, methylvinylene, ethylvinylene, 1- (or 2- or 3-)methylpropenylene, 1- (or 2- or 3-)ethylpropenylene, 1- (or 2- or 3- or 4-)methyl-l- (or 2-)butenylene, and the like.
- Suitable "cyclo(lower)alkyl” may include cyclopentyl, cyclohexyl and the like.
- Suitable “cyclo(lower) alkenyl” may include cyclohexenyl, cyclohexadienyl and the like.
- Suitable "aryl” may include phenyl, naphthyl and the like.
- halo (lower) alkyl [[ [halophenyl] (lower) alkenoyl]amino]- phenyl", “ [dihalophenyl] (lower)alkenyl” and 11 [halopyridylcarbonyl]amino” may include fluorine, bromine, chlorine and iodine.
- Suitable “leaving group” may include acid residue, lower alkoxy as exemplified above, and the like.
- Suitable “acid residue” may include halogen as exemplified above, acyloxy and the like.
- Suitable “halide” may include fluoride, bromide, chloride and the like.
- Suitable “protected carboxy” and “protected carboxy moiety” in the terms “[protected carboxypyridyl] (lower) - alkenyl and [[protected carboxy(lower)alkenyl]pyridyl]- (lower) alkenyl” may include esterified carboxy and the like.
- ester may be the ones such as lower alkyl ester (e.g., methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, t-pentyl ester, hexyl ester, etc.); lower alkenyl ester (e.g., vinyl ester, allyl ester, etc.); lower alkynyl ester (e.g.
- lower alkoxy(lower) alkyl ester e.g., methoxymethyl ester, ethoxymethyl ester, isopropoxymethyl ester, 1-methoxyethyl ester, 1-ethoxyethyl ester, etc.
- lower alkylthio (lower) alkyl ester e.g., methylthiomethyl ester, ethylthiomethyl ester, ethylthioethyl ester, isopropoxythiomethyl ester, etc.
- mono (or di or tri)halo (lower) alkyl ester e.g., 2- iodoethyl ester, 2,2,2-trichloroethyl ester, etc.
- lower alkanoyloxy(lower) alkyl ester e.g., acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester
- Suitable "hydroxy protective group" in the term "protected hydroxy” may include acyl, mono (or di or tri)phenyl (lower)alkyl which may have one or more suitable substituent (s) (e.g., benzyl, 4-methoxybenzyl, trityl, etc.), trisubstituted silyl [e.g., tri (lower) alkylsilyl (e.g., trimethylsilyl, t-butyldimethylsilyl, etc.), etc.], tetrahydropyranyl and the like.
- N-protective group may include acyl or a conventional protecting group such as mono (or di or tri) aryl (lower)alkyl, for example, mono(or di or tri)phenyl (lower) alkyl (e.g., benzyl, trityl, etc.) or the like.
- Suitable "protected amino” and “protected amino moiety” in the terms “[protected amino]phenyl", “[[[protected aminopyridyl] (lower) alkenoyl]amino]phenyl” and “[protected aminopyridyl] (lower)alkenyl] " may include acylamino or an amino group substituted by a conventional protecting group such as mono (or di or tri) aryl (lower) alkyl, for example, mono (or di or tri)phenyl (lower) alkyl (e.g., benzyl, trityl, etc.) or the like.
- acyl and “acyl moiety” in the terms “acylamino” and “acyloxy” may include carbamoyl, thiocarbamoyl, aliphatic acyl group and acyl group containing an aromatic ring, which is referred to as aromatic acyl, or heterocyclic ring, which is referred to as heterocyclic acyl.
- acyl may be illustrated as follows : Carbamoyl; Thiocarbamoyl;
- Aliphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.
- alkanoyl e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl
- lower or higher alkenoyl e.g., acryloyl, 2- (or 3-)- butenoyl, 2- (or 3- or 4-)pentenoyl, 2- (or 3- or 4- or 5-)- hexenoyl, etc.
- lower or higher alkoxycarbonyl e.g., methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc.
- lower or higher alkylsulfonyl e.g., methylsulfonyl, ethylsulfonyl, etc.
- lower or higher alkoxysulfonyl e.g., methoxysulfonyl, ethoxysulfonyl, etc.
- lower alkadienoyl e.g., heptadienoyl, hexa
- cycloheptylideneacetyl cycloheptylidenepropanoyl, cyclohexylideneacetyl, cyclohexylidenepropanoyl, etc.
- cyclo (lower) alkyloxycarbonyl e.g., cyclopentyloxycarbonyl, cyclohexyloxycarbonyl, etc.
- lower alkylglyoxyloyl e.g., methylglyoxyloyl, ethylglyoxyloyl, propylglyoxyloyl, etc.
- lower alkoxyglyoxyloyl e.g., methoxyglyoxyloyl, ethoxyglyoxyloyl, propoxyglyoxyloyl, etc.
- Aromatic acyl such as aroyl (e.g., benzoyl, toluoyl, naphthoyl, etc.); ar (lower) alkanoyl [e.g., phenyl (lower) alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl (lower)alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.), etc.]; ar(lower) alkenoyl [e.g., phenyl (lower)alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl, phen
- aryloxycarbonyl e.g., phenoxycarbonyl. naphthyloxycarbonyl, etc.
- aryloxy(lower) alkanoyl e.g., phenoxyacetyl, phenoxypropionyl, etc.
- arylglyoxyloyl e.g., phenylglyoxyloyl, naphthylglyoxyloyl, etc.
- arylsulfonyl e.g., phenylsulfonyl, p-tolylsulfonyl, etc.
- ar(lower)alkylsulfonyl e.g., phenyl (lower)alkylsulfonyl (e.g., benzylsulfonyl, phenylethylsulfonyl, etc.), naphthyl (lower) alkylsulfonyl (e.g., naphthylmethylsulfonyl, naphthylethylsulfonyl, etc.), etc.]; or the like;
- Heterocyclic acyl such as heterocycliccarbonyl; heterocyclic(lower)alkanoyl (e.g., heterocyclicacetyl, heterocyclicpropanoyl, heterocyclicbutanoyl, heterocyclicpentanoyl, heterocyclichexanoyl, etc.); heterocyclic (lower) alkenoyl (e.g., heterocyclicpropenoyl, heterocyclicbutenoyl, heterocyclicpentenoyl, heterocyclichexenoyl, etc.); heterocyclicglyoxyloyl; heterocyclicoxycarbonyl; or the like; in which suitable "heterocyclic moiety" in the terms "heterocycliccarbonyl", “heterocyclic(lower) alkanoyl", heterocyclic (lower) alkenoyl", heterocyclicoxycarbonyl and "heterocyclicglyoxyloyl” as mentioned above means, in more detail, saturated or unsaturated, mono
- heterocyclic group may be heterocyclic group such as unsaturated 3 to 8-membered (more preferably 5 or 6- me bered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 1H- 1,2,4-triazolyl, 4H-1,2, -triazolyl, 1H-1,2, 3-triazolyl, 2H-1,2, 3-triazolyl, etc.), tetrazolyl (e.g., IH-tetrazolyl, 2H-tetrazolyl, etc.), etc.; saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example,
- the acyl moiety as stated above may have one to ten, same or different, suitable substituent (s) such as lower alkyl as exemplified above, lower alkoxy as exemplified above, lower alkylthio wherein lower alkyl moiety is as exemplified above, cyclo (lower)alkyl as exemplified above, cyclo(lower)alkenyl as exemplified above, cyclo (lower) alkyloxy wherein cyclo (lower) alkyl moiety is as exemplified above, halogen as exemplified above, amino, protected amino as exemplified above, hydroxy, protected hydroxy as exemplified above, cyano, nitro, carboxy, protected carboxy as exemplified above, sulfo, sulfamoyl, imino, oxo, amino (lower) alkyl wherein lower alkyl moiety is as exemplified above, carb
- acyl thus defined may be aliphtic acyl such as lower alkanoyl (e.g. acetyl, etc.) and the most preferable one may be acetyl.
- lower alkanoyl e.g. acetyl, etc.
- Suitable "lower alkanoyl moiety" in the term "[lower alkanoylamino]phenyl” can be referred to the ones as mentioned above.
- the compound (I) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (III) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the compound (Ib) or a salt thereof can be prepared by subjecting the compound (Ia) or its reactive derivative at the amino group or a salt thereof to acylation reaction.
- Suitable acylating agent to be used in the present acylation reaction may include the compound of the formula :
- Suitable reactive derivative at the amino group of the compound (Ia) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (Ia) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (Ia) with a silyl compound such as N,0-bis (trimethylsilyl) acetamide, N-trimethylsilylacetamide or the like; a derivative formed by the reaction of the compound (Ia) with phosphorus trichloride or phosgene, and the like.
- Suitable reactive derivative of the compound (XXV) may include an acid halide, an acid anhydride, an activated ester, isocyanate, and the like.
- the suitable example may be an acid chloride; acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfuric acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.); aromatic carboxylic acid (e.
- the reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvents which do not adversely influence the reaction.
- a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvents which do not adversely influence the reaction.
- a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine
- the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide;
- 1-alkoxy-l-chloroethylene trialkyl phosphite; isopropyl polyphosphate; phosphorous oxychloride (phosphoryl chloride) ; phosphorous trichloride; thionyl chloride; oxalyl chloride; triphenylphosphite; 2-ethyl-7-hydroxybenzisoxazolium salt;
- the reaction may also be carried out in the presence of an organic or inorganic base such as an alkali metal bicarbonate, tri (lower) alkylamine, pyridine, N- (lower)alkylmorphorine, N,N-di (lower)alkylbenzylamine, or the like.
- an organic or inorganic base such as an alkali metal bicarbonate, tri (lower) alkylamine, pyridine, N- (lower)alkylmorphorine, N,N-di (lower)alkylbenzylamine, or the like.
- the reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.
- Process (3) The compound (Id) or a salt thereof can be prepared by subjecting the compound (lc) or a salt thereof to deacylation reaction.
- Suitable method of this deacylation reaction may include conventional one such as hydrolysis, reduction and the like.
- the hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.
- Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g., sodium, potassium, etc.], an alkaline earth metal [e.g., magnesium, calcium, etc.], the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine [e.g., trimethylamine, triethylamine, etc.], picoline, 1,5- diazabicyclo[4.3.0]non-5-ene, or the like.
- an alkali metal e.g., sodium, potassium, etc.
- an alkaline earth metal e.g., magnesium, calcium, etc.
- trialkylamine e.g., trimethylamine, triethylamine, etc.
- picoline 1,5- diazabicyclo[4.3.0]non-5-ene, or the like.
- Suitable acid may include an organic acid [e.g., formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], and an inorganic acid
- hydrochloric acid e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.
- Lewis acid such as trihaloacetic acid [e.g., trichloroacetic acid, trifluoroacetic acid, etc.], or the like is preferably carried out in the presence of cation trapping agents [e.g., anisole, phenol, etc.].
- cation trapping agents e.g., anisole, phenol, etc.
- the reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl, alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.
- a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl, alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
- Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.), or a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc. ) .
- hydrides e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.
- a metal e.g., tin, zinc, iron, etc.
- metallic compound
- Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, Ullman iron, etc.), and the like.
- platinum catalysts e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.
- palladium catalysts e.g., spongy palladium, palladium black, palla
- the reduction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.
- a solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.
- alcohol e.g., methanol, ethanol, isopropyl alcohol, etc.
- reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.
- the compound (If) or a salt thereof can be prepared by reacting the compound (Ie) or its reactive derivative at the amino group, or a salt thereof with the compound (IV) or its reactive drivative at the carboxy group, or a salt thereof.
- This reaction can be carried out in a similar manner to that of the aforementioned Process (2) , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (2) .
- the reaction conditions e.g., solvent, reaction temperature, etc.
- the compound (VII) or a salt thereof can be prepared by reacting the compound (Va) or a salt thereof with the compound (VI) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvents which do not adversely affect the reaction, or the mixture thereof.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvents which do not adversely affect the reaction, or the mixture thereof.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
- the reaction is usually carried out in the presence of an acid including Lewis acid.
- Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.] and the like.
- organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
- an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.
- the reaction may be also carried out in the presence of an inorganic or an organic base such as an alkali metal (e.g., sodium, potassium, etc.), an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), an alkali metal hydrogencarbonate (e.g., sodium hydrogencarbonate, potassium hydrogencarbonate, etc.), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), tri (lower) alkylamine (e.g., trimethylamine, triethylamine, diisopropylethylamine, etc.), alkali metal hydride (e.g., sodium hydride, etc.), alkali metal (lower)alkoxide (e.g., sodium methoxide, sodium ethoxide, etc.), pyridine, lutidine, picoline, dimethylaminopyridine, N- (lower) alkylmorpholine, N,N-di (lower
- the compound (Ig) or a salt thereof can be prepared by subjecting the compound (VII) or a salt thereof to elimination reaction of N-protective group.
- This reaction can be carried out in a similar manner to that of the aforementioned Process (3) , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (3) .
- the reaction conditions e.g., solvent, reaction temperature, etc.
- the compound (X) or a salt thereof can be prepared by reacting the compound (VIII) or a salt thereof with the compound (IX) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the starting compound is in liquid, it can be also used as a solvent.
- the compound (II) or a salt thereof can be prepared by subjecting the compound (X) or a salt thereof to reduction reaction.
- Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.) or a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).
- hydrides e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.
- a metal e.g., tin, zinc, iron, etc.
- metallic compound e.g
- Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel.
- platinum catalysts e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.
- palladium catalysts e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.
- nickel catalysts e.g., reduced nickel.
- nickel oxide, Raney nickel, etc. cobalt catalysts (e.g• I reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, etc.), copper catalysts (e.g., reduced copper, Raney copper, Ullman copper, etc.) and the like.
- the reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, alcohol (e.g., methanol, ethanol, propanol, etc.), tetrahydrofuran, dioxane, N, -dimethylformamide, etc., or a mixture thereof.
- a conventional solvent which does not adversely influence the reaction
- alcohol e.g., methanol, ethanol, propanol, etc.
- tetrahydrofuran e.g., dioxane
- N, -dimethylformamide, etc. e.g., N, -dimethylformamide, etc.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
- the compound (XI) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (XXIV) or a salt thereof.
- This reaction can be carried out in a similar manner to that of the aforementioned Process (1) , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (1) .
- the reaction conditions e.g., solvent, reaction temperature, etc.
- the compound (IX) or a salt thereof can be prepared by subjecting the compound (XII) or a salt thereof to reduction reaction.
- This reaction can be carried out in a similar manner to that of the aforementioned Process (B) , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (B) .
- the reaction conditions e.g., solvent, reaction temperature, etc.
- the compound (Ila) or a salt thereof can be prepared by subjecting the compound (XIII) or a salt thereof to elimination reaction of the amino protective group.
- the reaction can be carried out in the manner disclosed in Preparation 5 or 6 or similar manners thereto.
- the compound (Xb) or a salt thereof can be prepared by reacting the compound (Xa) or its reactive derivative at the amino group, or a salt thereof with the compound
- the reaction can be carried out in the manner disclosed in Preparation 16 or similar manners thereto.
- the compound (Xlla) or a salt thereof can be prepared by reacting the compound (XIV) with the compound (XV) or a salt thereof.
- the reaction can be carried out in the manner disclosed in Preparation 1 or similar manners thereto.
- the compound (IX) or a salt thereof can be prepared by reacting the compound (XVII) or a salt thereof with the compound (XVIII) or a salt thereof.
- the reaction can be carried out in the manner disclosed in Preparation 3, or similar manners thereto.
- the compound (Xc) or a salt thereof can be prepared by reacting the compound (XIX) or a salt thereof with the compound (XX) .
- the compound (V) or a salt thereof can be prepared by subjecting the compound (XI) or a salt thereof to halogenation reaction.
- the reaction can be carried out in the manner disclosed in Preparation 25 or similar manners thereto.
- the compound (XXIIa) or a salt thereof can be prepared by reacting the compound (XIV) with the compound (XXI) or a salt thereof.
- the reaction can be carried out in the manner disclosed in Preparation 2 or similar manners thereto.
- the compound (XIIb) or a salt thereof can be prepared by reacting the compound (XXII) or a salt thereof with the compound (XXIII) or a salt thereof.
- the reaction can be carried out in the manner disclosed in Preparation 12 or similar manners thereto.
- Suitable salts of the object and the starting compounds in Processes (l)p(5) and (A)£>(L) can be referred to the ones as exemplified for the compound (I) .
- the new pyridopyrazine derivatives (I) and pharmaceutically acceptable salts thereof hardly possess a strong inhibitory activity against phosphodiesterase III (PDE III), but possess a strong inhibitory activity against phosphodiesterase IV (PDE IV) and a strong inhibitory activity on the tumor necrosis factor (TNF) .
- the pyridopyrazine derivatives (I) and pharmaceutically acceptable salts thereof are selective inhibitors of phosphodiesterase IV (PDE IV) and inhibitors on the production of tumor necrosis factor (TNF) .
- PDE IV phosphodiesterase IV
- TNF tumor necrosis factor
- the new pyridopyrazine derivatives (I) and a pharmaceutically acceptable salt thereof can be used for prophylactic and therapeutic treatment of PDE-IV and TNF mediated diseases such as chronic inflammatory diseases (e.g., rheumatoid arthritis, osteoarthritis, emphysema, chronic bronchiolitis, etc.), osteoporosis, rejection by transplantation, asthma, eosinophilia, cystic fibrosis, hepatitis, pancreatitis, nephritis, endotoxin shock, specific autoimmune diseases [e.g., ankylosing spondylitis, autoimmune hematological disorders (e
- Grave's disease sarcoidosis, multiple sclerosis, primary biliary cirrhosis, diabetes [e.g. juvenile diabetes (diabetes mellitus type I), etc.], Reiter's syndrome, non infection uveitis, autoimmune keratitis (e.g., keratoconjunctivitis sicca, vernal keratoconjunctivitis, etc.), interstitial lung fibrosis, psoriatic arthritis, etc.], cancer cachexia, AIDS cachexia, thrombosis, and the like.
- diabetes e.g. juvenile diabetes (diabetes mellitus type I), etc.]
- Reiter's syndrome non infection uveitis
- autoimmune keratitis e.g., keratoconjunctivitis sicca, vernal keratoconjunctivitis, etc.
- interstitial lung fibrosis psoriatic arthritis, etc.
- the washed cell pellet was homogenized with Dounce homogenizer (20 strokes) in homogenizing buffer (0.5 % deoxycholate [DOC] , 5 mM 2-mercaptoethanol, 1 ⁇ M leupeptin, 100 ⁇ M PMSF, 20 ⁇ M p-tosyl-L-lysine- chloromethyl ketone [TLCK] in PBS) .
- the homogenate was centrifuged at 100,000 g x 90 minutes (4pC) and the supernatant containing PDE IV activity was dialyzed against dialysis buffer, which was the same component as homogenizing buffer without DOC.
- the dialyzed supernatant of homogenate was stored in freezer (-80pC) as PDE IV enzyme preparation.
- Enzyme preparation was diluted in assay buffer (10 mM Tris-HCl, 5 mM MgCl, 1 mM 2-Mercaptoethanol [pH 8.0]). In advance the rate of dilution was choosen every new lot of homogenizing preparation. For blank, a part of the enzyme preparation was boiled for 10 minutes.
- Test compounds were dissolved in dimethylsulfoxide (DMSO) at a concentration of 4 x 10(-2) [M] (final cone. 1 x 10(-5)M), then serial dilutions were made in DMSO to achieve desired concentrations. The diluted compounds of each concentration were further diluted 1:500 in assay buffer (0.2% DMSO) . Final DMSO concentration in assay tube was 0.025%.
- DMSO dimethylsulfoxide
- the inhibitory activity was calculated according to the following equation : avg.cp [test compound] - avg.cpm[blank (boiled enzyme)]
- MNC mononuclear cell
- MNC were incubated at 37bC for 16 hours in 96-well micro culture plate at a concentration of 3 x IO 5 cells/well with or without 1 ⁇ g/ml lipopolysaccharide (LPS) (from E. coli) and various amounts of test compound.
- LPS lipopolysaccharide
- the supernatant was obtained and its TNF- ⁇ active was measured by enzyme-linked immunosorbent assay (ELISA) .
- ELISA enzyme-linked immunosorbent assay
- the object compounds [ I ) of the present invention and pharmaceutically acceptable salts thereof are used in a form of the conventional pharmaceutical preparation in admixture with a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration.
- a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration.
- the pharmaceutical preparation may be compounded in a solid form such as granule, capsule, tablet, dragee or suppository, or in a liquid form such as solution, suspension or emulsion for injection, ingestion, eye drops, etc. If needed, there may be included in the above preparation auxiliary substance such as stabilizing agent, wetting or emulsifying agent, buffer or any other commonly used additives.
- the effective ingredient may usually be administered with a unit dose of 0.001 mg/kg to 500 mg/kg, preferably 0.01 mg/kg to 10 mg/kg, 1 to 4 times a day.
- the above dosage may be increased or decreased according to age, weight and conditions of the patient or the administering method.
- Preferred embodiments of the object compound (I) are as follows.
- R 1 is pyridyl (lower)alkyl, N-oxidopyridyl (lower) alkyl or imidazolyl (lower)alkyl,
- R is aminophenyl, [lower alkanoylamino]phenyl,
- R ⁇ is N-oxidopyridyl (lower) alkyl or imidazolyl (lower) alkyl.
- Example 5 To a solution of 4- [3-[ (E)-2- (3, 5-dichlorophenyl)- vinyl]phenyl]-2- (3-pyridylmethyl) -3-oxo-3, 4-dihydropyrido- [2, 3-b]pyrazine (255 mg) in dichloromethane (10 ml) was added m-chloroperbenzoic acid (181 mg) . The mixture was stirred at room temperature for 1 hour, then poured into aqueous sodium bicarbonate and extracted with chloroform. The organic solution was washed with aqueous sodium bicarbonate and brine, dried over magnesium sulfate and concentrated.
- Example 12 To a stirred suspension of 2- (3-pyridyl)thiazole-4- carboxylic acid (0.56 g) and triethylamine (0.55 g) in methylene chloride (25 ml) was added pivaloyl chloride (0.33 g) in methylene chloride (5 ml) and the mixture was stirred for 2 hours. After the reaction mixture was cleared, 4- [3- (3-aminophenyl)phenyl]-2- (3-pyridylmethyl) - 3-OXO-3, 4-dihydropyrido [2, 3-b]pyrazine (1.0 g) was added thereto and the mixture was stirred under reflux for 2 hours.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9524170A JP2000502699A (en) | 1995-12-27 | 1996-12-13 | Pyrido (2,3-B) pyrazine derivative |
AT96941882T ATE214067T1 (en) | 1995-12-27 | 1996-12-13 | PYRIDO (2,3-B) PYRAZINE DERIVATIVES |
EA199800599A EA001324B1 (en) | 1995-12-27 | 1996-12-13 | Heterobicyclic derivatives |
IL12467396A IL124673A (en) | 1995-12-27 | 1996-12-13 | 2-SUBSTITUTED-4-(SUBSTITUTED PHENYL) PYRIDO [2, 3-b] PYRAZIN-3 (4H)-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
KR1019980704348A KR19990072053A (en) | 1995-12-27 | 1996-12-13 | Pyrido (2,3-B) pyrazine Derivatives |
US09/091,361 US6117875A (en) | 1995-12-27 | 1996-12-13 | Pyrido (2,3-B) pyrazine derivatives |
DE69619702T DE69619702T2 (en) | 1995-12-27 | 1996-12-13 | PYRIDO (2,3-B) PYRAZINE DERIVATIVES |
EP96941882A EP0874845B1 (en) | 1995-12-27 | 1996-12-13 | Pyrido (2,3-b) pyrazine derivatives |
DK96941882T DK0874845T3 (en) | 1995-12-27 | 1996-12-13 | Pyrido [2,3-b] pyrazine derivatives |
AU11112/97A AU720301B2 (en) | 1995-12-27 | 1996-12-13 | Heterobicyclic derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9526558.3A GB9526558D0 (en) | 1995-12-27 | 1995-12-27 | Heterobicyclic derivatives |
GB9526558.3 | 1995-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997024355A1 true WO1997024355A1 (en) | 1997-07-10 |
Family
ID=10786098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/003666 WO1997024355A1 (en) | 1995-12-27 | 1996-12-13 | Pyrido (2,3-b) pyrazine derivatives |
Country Status (18)
Country | Link |
---|---|
US (1) | US6117875A (en) |
EP (1) | EP0874845B1 (en) |
JP (1) | JP2000502699A (en) |
KR (1) | KR19990072053A (en) |
CN (1) | CN1066732C (en) |
AT (1) | ATE214067T1 (en) |
AU (1) | AU720301B2 (en) |
CA (1) | CA2241690A1 (en) |
DE (1) | DE69619702T2 (en) |
DK (1) | DK0874845T3 (en) |
EA (1) | EA001324B1 (en) |
ES (1) | ES2170286T3 (en) |
GB (1) | GB9526558D0 (en) |
HU (1) | HUP9901038A3 (en) |
IL (1) | IL124673A (en) |
MX (1) | MX9805129A (en) |
PT (1) | PT874845E (en) |
WO (1) | WO1997024355A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001092229A1 (en) * | 2000-05-31 | 2001-12-06 | Santen Pharmaceutical Co., Ltd. | TNF-α PRODUCTION INHIBITORS |
WO2004041819A1 (en) * | 2002-11-06 | 2004-05-21 | Grelan Pharmaceutical Co., Ltd. | Pyrazolonaphthyridine derivative |
WO2005094822A1 (en) * | 2004-03-22 | 2005-10-13 | Eli Lilly And Company | Pyridyl derivatives and their use as mglu5 receptor antagonists |
WO2006126081A2 (en) * | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
US7199140B2 (en) | 2001-06-26 | 2007-04-03 | Astrazeneca Ab | Vinyl phenyl derivatives as GLK activators |
US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2009109341A1 (en) | 2008-03-05 | 2009-09-11 | Merck Patent Gmbh | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
EP2193808A1 (en) | 1999-08-21 | 2010-06-09 | Nycomed GmbH | Synergistic combination |
WO2010096426A2 (en) * | 2009-02-20 | 2010-08-26 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
BR0107733A (en) | 2000-01-20 | 2003-03-11 | Eisai Co Ltd | Compound, its use, pharmaceutical composition, method for preventing, treating or ameliorating a disease against which a calcium antagonist is effective, method for suppressing neural brain death or protecting a brain neural cell, and method for preventing, treating or ameliorating neural disease. or pain |
US20080280891A1 (en) * | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
CN101875627B (en) * | 2009-04-30 | 2014-01-15 | 凯惠科技发展(上海)有限公司 | 1-carbalkoxy-2H-isoindazole derivative, preparation method and intermediate thereof |
EP3967687A4 (en) * | 2019-05-10 | 2023-01-18 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd | Substituted phenylpropenylpyridine derivative, and preparation method therefor and medical use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0008864A1 (en) * | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them |
WO1996001825A1 (en) * | 1994-07-11 | 1996-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Heterobicyclic derivatives |
-
1995
- 1995-12-27 GB GBGB9526558.3A patent/GB9526558D0/en active Pending
-
1996
- 1996-12-13 KR KR1019980704348A patent/KR19990072053A/en not_active Application Discontinuation
- 1996-12-13 DE DE69619702T patent/DE69619702T2/en not_active Expired - Fee Related
- 1996-12-13 AU AU11112/97A patent/AU720301B2/en not_active Ceased
- 1996-12-13 CA CA002241690A patent/CA2241690A1/en not_active Abandoned
- 1996-12-13 AT AT96941882T patent/ATE214067T1/en not_active IP Right Cessation
- 1996-12-13 EP EP96941882A patent/EP0874845B1/en not_active Expired - Lifetime
- 1996-12-13 ES ES96941882T patent/ES2170286T3/en not_active Expired - Lifetime
- 1996-12-13 HU HU9901038A patent/HUP9901038A3/en unknown
- 1996-12-13 WO PCT/JP1996/003666 patent/WO1997024355A1/en not_active Application Discontinuation
- 1996-12-13 US US09/091,361 patent/US6117875A/en not_active Expired - Fee Related
- 1996-12-13 IL IL12467396A patent/IL124673A/en not_active IP Right Cessation
- 1996-12-13 EA EA199800599A patent/EA001324B1/en not_active IP Right Cessation
- 1996-12-13 JP JP9524170A patent/JP2000502699A/en active Pending
- 1996-12-13 PT PT96941882T patent/PT874845E/en unknown
- 1996-12-13 DK DK96941882T patent/DK0874845T3/en active
- 1996-12-13 CN CN96199282A patent/CN1066732C/en not_active Expired - Fee Related
-
1998
- 1998-06-24 MX MX9805129A patent/MX9805129A/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0008864A1 (en) * | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them |
WO1996001825A1 (en) * | 1994-07-11 | 1996-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Heterobicyclic derivatives |
Non-Patent Citations (1)
Title |
---|
S. HAYASHI ET AL.: "Antispasmodic action of 1-diethylaminoethyl-3-(p-methoxybenzyl)-2-quinoxalone (P 201-I) and its inhibitory effect on cyclic 3',5'-nucleotide phosphodiesterase (PDE) activity", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 23, no. 4, 1975, TOKYO JP, pages 810 - 816, XP002027162 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2193808A1 (en) | 1999-08-21 | 2010-06-09 | Nycomed GmbH | Synergistic combination |
WO2001092229A1 (en) * | 2000-05-31 | 2001-12-06 | Santen Pharmaceutical Co., Ltd. | TNF-α PRODUCTION INHIBITORS |
AU2001260674B2 (en) * | 2000-05-31 | 2006-03-30 | Ayumi Pharmaceutical Corporation | Tnf-alpha production inhibitors |
US7098226B2 (en) | 2000-05-31 | 2006-08-29 | Santen Pharmaceutical Co., Ltd. | TNF-α production inhibitors |
US7923461B2 (en) * | 2000-05-31 | 2011-04-12 | Santen Pharmaceutical Co., Ltd. | TNF-α production inhibitors |
US7345064B2 (en) | 2000-05-31 | 2008-03-18 | Santen Pharmaceutical Co., Ltd. | TNF-α production inhibitors |
US7491739B2 (en) | 2000-05-31 | 2009-02-17 | Santen Pharmaceutical Co., Ltd. | TNF-α production inhibitors |
US7199140B2 (en) | 2001-06-26 | 2007-04-03 | Astrazeneca Ab | Vinyl phenyl derivatives as GLK activators |
WO2004041819A1 (en) * | 2002-11-06 | 2004-05-21 | Grelan Pharmaceutical Co., Ltd. | Pyrazolonaphthyridine derivative |
AU2003277562B2 (en) * | 2002-11-06 | 2009-03-26 | Aska Pharmaceutical Co., Ltd. | Pyrazolonaphthyridine derivative |
US7608716B2 (en) | 2002-11-06 | 2009-10-27 | Aska Pharmaceutical Co., Ltd. | Pyrazolonaphthyridine derivative |
US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2005094822A1 (en) * | 2004-03-22 | 2005-10-13 | Eli Lilly And Company | Pyridyl derivatives and their use as mglu5 receptor antagonists |
US7915424B2 (en) | 2004-03-22 | 2011-03-29 | Eli Lilly And Company | Pyridyl derivatives and their use as mGlu5 antagonists |
WO2006126081A3 (en) * | 2005-05-24 | 2007-01-18 | Pharmacia & Upjohn Co Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
WO2006126081A2 (en) * | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
WO2009109341A1 (en) | 2008-03-05 | 2009-09-11 | Merck Patent Gmbh | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
US8178556B2 (en) | 2008-03-05 | 2012-05-15 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
US8609689B2 (en) | 2008-03-05 | 2013-12-17 | Merck Patent Gmbh | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
US8642617B2 (en) | 2008-03-05 | 2014-02-04 | Merck Patent Gmbh | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
AU2009221213B2 (en) * | 2008-03-05 | 2014-02-27 | Merck Patent Gmbh | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
EA020372B1 (en) * | 2008-03-05 | 2014-10-30 | Мерк Патент Гмбх | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
WO2010096426A2 (en) * | 2009-02-20 | 2010-08-26 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
WO2010096426A3 (en) * | 2009-02-20 | 2011-01-27 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
Also Published As
Publication number | Publication date |
---|---|
US6117875A (en) | 2000-09-12 |
CN1066732C (en) | 2001-06-06 |
MX9805129A (en) | 1998-10-31 |
GB9526558D0 (en) | 1996-02-28 |
HUP9901038A3 (en) | 2000-04-28 |
ATE214067T1 (en) | 2002-03-15 |
HUP9901038A2 (en) | 1999-07-28 |
DE69619702T2 (en) | 2002-08-14 |
IL124673A0 (en) | 1998-12-06 |
PT874845E (en) | 2002-08-30 |
JP2000502699A (en) | 2000-03-07 |
EP0874845A1 (en) | 1998-11-04 |
CA2241690A1 (en) | 1997-07-10 |
DE69619702D1 (en) | 2002-04-11 |
DK0874845T3 (en) | 2002-07-01 |
EP0874845B1 (en) | 2002-03-06 |
KR19990072053A (en) | 1999-09-27 |
EA001324B1 (en) | 2001-02-26 |
ES2170286T3 (en) | 2002-08-01 |
AU1111297A (en) | 1997-07-28 |
AU720301B2 (en) | 2000-05-25 |
IL124673A (en) | 2002-07-25 |
CN1205702A (en) | 1999-01-20 |
EA199800599A1 (en) | 1998-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0770079B1 (en) | Heterobicyclic derivatives | |
US5356897A (en) | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines | |
US5670503A (en) | Pyrazole derivatives | |
AU656576B2 (en) | Quinoline derivatives | |
WO1992012154A1 (en) | Imidazotriazine derivatives | |
EP0874845B1 (en) | Pyrido (2,3-b) pyrazine derivatives | |
WO1992002513A1 (en) | Heterocyclic compounds | |
US5583135A (en) | Heterotricyclic derivatives, process for their preparation and pharmaceutical compositions containing them | |
JPH05213971A (en) | Novel cephem compounds | |
US5958914A (en) | Cephem compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96199282.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN HU IL JP KR MX US AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996941882 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980704348 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09091361 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/005129 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2241690 Country of ref document: CA Ref document number: 2241690 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 199800599 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1996941882 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980704348 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996941882 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980704348 Country of ref document: KR |